V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Johnson & Johnson Executive Compensation (FY25)

JNJ · New Brunswick, NJ · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): April 28, 2026
410 figures on this page: 401 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
Joaquin Duato was paid $32,758,111 in total compensation as Chairman/CEO for fiscal 2025, and Duato's total was 34.8% higher than the $24,302,360 reported for fiscal 2024. The company reported a chief executive pay ratio of 360:1 for fiscal 2025, against median employee compensation of $91,000. The say-on-pay proposal drew 94.7% of votes cast for or against in favor at the meeting held April 23, 2026 for fiscal 2025. Companies named in the disclosed peer group include Abbott Laboratories, Abbvie Inc., Amgen Inc., AT T Inc. and Bristol Myers Squibb Company, among others.
Chief executive, fiscal 2025
◇
Joaquin Duato
Latest say-on-pay support
=
April 23, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Joaquin Duato: $24,302,360 → $32,758,111 (34.8% higher)
Say-on-pay support: 91.6% → 94.7% (3.1 points higher)
CEO pay ratio: 293:1 → 360:1 (22.9% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Johnson & Johnson's chief executive and what were they paid?
Joaquin Duato was paid $32,758,111 in total compensation as Chairman/CEO for fiscal 2025. Duato's total was 34.8% higher than the $24,302,360 reported for fiscal 2024.
What was Johnson & Johnson's say-on-pay result?
The say-on-pay proposal drew 94.7% of votes cast for or against in favor at the meeting held April 23, 2026 for fiscal 2025.
Which companies are in Johnson & Johnson's peer group?
Companies named in the disclosed peer group include Abbott Laboratories, Abbvie Inc., Amgen Inc., AT T Inc. and Bristol Myers Squibb Company, among others.
What is Johnson & Johnson's chief executive pay ratio?
The company reported a chief executive pay ratio of 360:1 for fiscal 2025, against median employee compensation of $91,000.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joaquin Duato
Chairman & Chief Executive Officer
◇—◇◇◇—◇◇
Joseph Wolk
Executive Vice President, Chief Financial Officer
◇—◇◇◇—◇◇
Jennifer Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
◇—◇◇◇—◇◇
Ashley McEvoy
Executive Vice President, Worldwide Chairman, MedTech
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joaquin Duato
Chairman & Chief Executive Officer
◇—◇◇◇◇◇◇
John Reed
Executive Vice President, Global Head, Innovative Medicine R&D
◇◇◇—◇◇◇◇
Joseph Wolk
Executive Vice President, Chief Financial Officer
◇—◇◇◇◇◇◇
Jennifer Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
◇—◇◇◇◇◇◇
Ashley McEvoy
Executive Vice President, Worldwide Chairman, MedTech
◇—◇◇◇◇◇◇
Peter Fasolo
Executive Vice President, Chief Human Resources Officer
◇—◇◇◇◇◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joaquin Duato
Chairman of the Board and Chief Executive Officer
◇—◇◇◇◇◇◇
Joseph Wolk
Executive Vice President, Chief Financial Officer
◇—◇◇◇◇◇◇
Tim Schmid
EVP, Worldwide Chairman, MedTech
◇—◇◇◇◇◇◇
Jennifer Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
◇—◇◇◇◇◇◇
John Reed
Executive Vice President, Innovative Medicine, R&D
◇—◇◇◇◇◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Joaquin Duato
Chairman/CEO
◇—◇◇◇◇◇◇
Joseph Wolk
EVP, CFO
◇—◇◇◇◇◇◇
Jennifer Taubert
EVP, WWC Innovative Medicine
◇—◇◇◇◇◇◇
John Reed
EVP, Innovative Medicine, R&D
◇—◇◇◇◇◇◇
Tim Schmid
EVP, WWC, MedTech
◇—◇◇◇◇◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Jennifer TaubertPSU◇——◇——◇
Jennifer TaubertOPTION◇——◇—◇◇
Jennifer TaubertRSU◇——◇——◇
Joaquin DuatoOPTION◇——◇—◇◇
Joaquin DuatoRSU◇——◇——◇
Joaquin DuatoPSU◇——◇——◇
John ReedRSU◇——◇——◇
John ReedOPTION◇——◇—◇◇
John ReedPSU◇——◇——◇
Joseph WolkRSU◇——◇——◇
Joseph WolkOPTION◇——◇—◇◇
Joseph WolkPSU◇——◇——◇
Tim SchmidRSU◇——◇——◇
Tim SchmidOPTION◇——◇—◇◇
Tim SchmidPSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Joaquin DuatoRSU◇◇——
Option◇—◇2/15/2035
Option◇—◇2/13/2027
RSU◇◇——
Option◇—◇2/12/2028
RSU◇◇——
Option◇—◇2/8/2031
Option◇—◇2/14/2032
Option◇—◇2/13/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/15/2034
Option◇—◇2/11/2029
Option◇—◇2/10/2030
Jennifer TaubertRSU◇◇——
Option◇—◇2/13/2027
Option◇—◇2/11/2029
Option◇—◇2/14/2032
RSU◇◇——
RSU◇◇——
Option◇—◇2/15/2034
Option◇—◇2/13/2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/12/2028
Option◇—◇2/8/2031
Option◇—◇2/15/2035
Option◇—◇2/10/2030
Joseph WolkRSU◇◇——
RSU◇◇——
Option◇—◇2/10/2030
Option◇—◇2/14/2032
Option◇—◇2/11/2029
Option◇—◇2/15/2034
Option◇—◇2/8/2031
RSU◇◇——
Option◇—◇2/13/2033
Option◇—◇2/13/2027
Option◇—◇2/12/2028
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/15/2035
John ReedRSU◇◇——
Option◇—◇2/15/2035
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/15/2034
Tim SchmidRSU◇◇——
Option◇—◇2/15/2035
RSU◇◇——
Option◇—◇2/15/2034
Option◇—◇2/8/2026
Option◇—◇2/8/2031
Option◇—◇2/13/2027
Option◇—◇2/11/2029
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇2/13/2033
Option◇—◇2/12/2028
Option◇—◇2/14/2032
Option◇—◇2/10/2030
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Marillyn A. Hewson
Lead independent director
◇◇———◇◇
Mary C. Beckerle
◇◇———◇◇
Jennifer A. Doudna
◇◇———◇◇
Hubert Joly
◇◇———◇◇
Mark A. Weinberger
◇◇————◇
Nadja Y. West
◇◇———◇◇
Eugene A. Woods
◇◇————◇
Paula A. Johnson
◇◇———◇◇
Mark B. McClellan
◇◇————◇
Darius Adamczyk
◇—————◇
Daniel E. Pinto
◇—————◇
John G. Morikis
◇————◇◇
Anne M. Mulcahy
◇—————◇
Joaquin Duato served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as Deferred Share Units.
Stock ownership guideline: 5x annual cash retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Abbott Laboratories ABT
  • Abbvie Inc. ABBV
  • Amgen Inc. AMGN
  • AT T Inc. T
  • Bristol Myers Squibb Company BMY
  • Company (ticker symbol) symbol not shown
  • Eli Lilly and Company LLY
  • Intel Corporation INTC
  • Medtronic plc MDT
  • Merck Co., Inc. MRK
  • Microsoft Corporation (MSFT)(9) MSFT
  • Pfizer Inc. PFE
  • RTX Corporation RTX
  • The Boeing Company BA

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 23, 2026=◇◇◇
2024April 24, 2025=◇◇◇
2023April 25, 2024=◇◇◇
2022April 27, 2023=◇◇◇
2021April 28, 2022=◇◇◇
2020April 22, 2021=◇◇◇
2019April 23, 2020=◇◇◇
2018April 25, 2019=◇◇◇
2017April 26, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Johnson & Johnson files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Johnson & Johnson disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Johnson & Johnson sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Johnson & Johnson's disclosed peer group is defensible, who names Johnson & Johnson back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
410 figures on this page: 401 cited to the filing that reported them, 9 calculated from figures it prints.
401 cited to the filing
9 calculated from the filing

Documents cited

  1. 0000200406-26-000089
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000200406-26-000063
    Audit Committee · Board Committee responsibilities · CEO Pay Ratio · EVP, WWC I · and 3 more sections
  3. 0000200406-25-000141
  4. 0000200406-25-000099
    2024 Summary compensation table
  5. 0000200406-24-000043
  6. 0000200406-24-000024
    2023 Summary compensation table
  7. 0000200406-23-000059
  8. 0000200406-23-000023
    Summary Compensation Table
  9. 0000200406-22-000047
  10. 0000200406-21-000030
  11. 0000200406-20-000034
  12. 0000200406-19-000028
  13. 0000200406-18-000017
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Johnson & Johnson executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/JNJ (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Johnson & Johnson and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Johnson & Johnson discloses

The companies named in JNJ's own disclosed peer group.

Abbott LaboratoriesAbbvie Inc.Amgen Inc.Bristol Myers Squibb CompanyEli Lilly and CompanyIntel CorporationMedtronic plcMerck Co., Inc.Microsoft Corporation (MSFT)(9)Pfizer Inc.The Boeing Company

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy